All In Biotech

Drug Trial Radar · NCT07844148

A Study to Compare GNR-139 and Eylea® in Patients With nAMD

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of GNR-139 in Comparison With Eylea® (114.3 mg/mL) in Patients With nAMD

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind study designed to compare the efficacy and safety of the investigational drug GNR-139 with the reference drug Eylea in treatment-naive patients with neovascular age-related macular degeneration (nAMD). Participants will be randomly assigned to receive either GNR-139 or Eylea. Neither the participants nor the study doctors will know which treatment is being administered. Both drugs will be given as an intravitreal injection dose of 8 mg (0.07 mL at a concentration of 114.3 mg/mL). Patients meeting the eligibility criteria will be randomised in a 2:1 ratio into one of two treatment groups: * Group I (GNR-139): 120 patients; * Group II (Eylea®): 60 patients. The main goal of the study is to evaluate if GNR-139 has similar efficacy to Eylea. This will be determined by measuring the change in the Best-Corrected Visual Acuity (BCVA) score at Week 8 in participants who completed the treatment.

Conditions

  • nAMD

Interventions

  • afliberceptBiological

    GNR-139 is being developed as a biosimilar to the reference medicinal product Eylea®

  • EyleaBiological

    Eylea® (INN: aflibercept), 114.3 mg/mL, solution for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in BCVA, assessed by the number of letters read correctly on the ETDRS chart, at Week 8.Time frame: Week 8

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Cheboksary branch of S. Fyodorov Eye Microsurgery Federal State Institution

    Cheboksary, Cheboksary, Russia · Not yet recruiting

  • Medical organization "Optic-Center" Ltd

    Chelyabinsk, Chelyabinsk Oblast, Russia · Not yet recruiting

  • Sverdlovsk Regional Clinical Hospital No.1

    Yekaterinburg, Ekaterinburg, Russia · Not yet recruiting

  • Ivanovo regional clinical hospital

    Ivanovo, Ivanovo Oblast, Russia · Recruiting

  • Federal State Budgetary Institution "Helmholtz National Medical Research Center of Eye Diseases" of the Ministry of Health of the Russian Federation

    Moscow, Moscow, Russia · Not yet recruiting

  • Federal State Budgetary Educational Institution of Higher Education "Russian University of Medicine"

    Moscow, Moscow, Russia · Not yet recruiting

  • S.Fyodorov Eye Microsurgery Federal State Institution

    Moscow, Moscow, Russia · Not yet recruiting

  • Volga District Medical Center of the Federal Medical and Biological Agency

    Nizhny Novgorod, Nizhny Novgorod Oblast, Russia · Recruiting

  • Novosibirsk Regional Clinical Hospital

    Novosibirsk, Novosibirsk Oblast, Russia · Not yet recruiting

  • V.P. Vykhodtsev Clinical Ophthalmology Hospital

    Omsk, Omsk Oblast, Russia · Not yet recruiting

  • S.M. Kirov Military Medical Academy

    Saint Petersburg, Saint Peterburg, Russia · Not yet recruiting

  • X7 Clinical Research Co

    Saint Petersburg, Saint Peterburg, Russia · Not yet recruiting

  • LLC "Eye Diseases Clinic"

    Kazan', Tatarstan Republic, Russia · Not yet recruiting

  • LLC Eyes Clinic-Opticstyle

    Vladimir, Vladimirskaya Oblast’, Russia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.